Keymed Biosciences (HKG:2162) raised net proceeds of HK$853.8 million through a top-up placement, a Thursday Hong Kong bourse filing said.
21.6 million shares were placed by substantial shareholder Moonshot at HK$45.48 apiece to at least six investors.
The biopharmaceutical firm then issued 19 million shares to Moonshot, representing 6.36% of its enlarged issued share capital.
The drug company will use proceeds from the issue for R&D expenses, commercialization of Stapokibart, the capital expenditure of manufacturing and R&D facilities, and general corporate and working capital.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。